183 related articles for article (PubMed ID: 31645902)
1. Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity.
Woodford MR; Hughes M; Sager RA; Backe SJ; Baker-Williams AJ; Bratslavsky MS; Jacob JM; Shapiro O; Wong M; Bratslavsky G; Bourboulia D; Mollapour M
Oncotarget; 2019 Oct; 10(56):5824-5834. PubMed ID: 31645902
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.
Woodford MR; Sager RA; Marris E; Dunn DM; Blanden AR; Murphy RL; Rensing N; Shapiro O; Panaretou B; Prodromou C; Loh SN; Gutmann DH; Bourboulia D; Bratslavsky G; Wong M; Mollapour M
EMBO J; 2017 Dec; 36(24):3650-3665. PubMed ID: 29127155
[TBL] [Abstract][Full Text] [Related]
3. Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer.
Backe SJ; Sager RA; Meluni KA; Woodford MR; Bourboulia D; Mollapour M
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883484
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
5. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
6. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
Jiang WG; Sampson J; Martin TA; Lee-Jones L; Watkins G; Douglas-Jones A; Mokbel K; Mansel RE
Eur J Cancer; 2005 Jul; 41(11):1628-36. PubMed ID: 15951164
[TBL] [Abstract][Full Text] [Related]
7. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
Aicher LD; Campbell JS; Yeung RS
J Biol Chem; 2001 Jun; 276(24):21017-21. PubMed ID: 11290735
[TBL] [Abstract][Full Text] [Related]
8. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
Nellist M; Verhaaf B; Goedbloed MA; Reuser AJ; van den Ouweland AM; Halley DJ
Hum Mol Genet; 2001 Dec; 10(25):2889-98. PubMed ID: 11741832
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of 18 families with tuberous sclerosis complex.
Yin K; Lin N; Lu Q; Jin L; Huang Y; Zhou X; Xu K; Liu Q; Zhang X
Neurogenetics; 2022 Jul; 23(3):223-230. PubMed ID: 35596872
[TBL] [Abstract][Full Text] [Related]
10. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
11. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
Benvenuto G; Li S; Brown SJ; Braverman R; Vass WC; Cheadle JP; Halley DJ; Sampson JR; Wienecke R; DeClue JE
Oncogene; 2000 Dec; 19(54):6306-16. PubMed ID: 11175345
[TBL] [Abstract][Full Text] [Related]
12. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
Mak BC; Takemaru K; Kenerson HL; Moon RT; Yeung RS
J Biol Chem; 2003 Feb; 278(8):5947-51. PubMed ID: 12511557
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.
Jones AC; Daniells CE; Snell RG; Tachataki M; Idziaszczyk SA; Krawczak M; Sampson JR; Cheadle JP
Hum Mol Genet; 1997 Nov; 6(12):2155-61. PubMed ID: 9328481
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
Fackler I; DeClue JE; Rust H; Vu PA; Kutzner H; Rütten A; Kaddu S; Sander CA; Volkenandt M; Johnson MW; Vinters HV; Wienecke R
J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis as an underlying basis for infantile spasm.
Yeung RS
Int Rev Neurobiol; 2002; 49():315-32. PubMed ID: 12040899
[TBL] [Abstract][Full Text] [Related]
16. Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis.
Sager RA; Woodford MR; Shapiro O; Mollapour M; Bratslavsky G
Oncotarget; 2018 Apr; 9(31):22220-22229. PubMed ID: 29774133
[TBL] [Abstract][Full Text] [Related]
17. Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.
Pilipow K; Basso V; Migone N; Mondino A
PLoS One; 2014; 9(3):e91952. PubMed ID: 24633152
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin.
Nellist M; van Slegtenhorst MA; Goedbloed M; van den Ouweland AM; Halley DJ; van der Sluijs P
J Biol Chem; 1999 Dec; 274(50):35647-52. PubMed ID: 10585443
[TBL] [Abstract][Full Text] [Related]
19. The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dubé and Tuberous Sclerosis Complex Syndromes.
Woodford MR; Backe SJ; Sager RA; Bourboulia D; Bratslavsky G; Mollapour M
Urol Oncol; 2021 Jun; 39(6):322-326. PubMed ID: 32327294
[TBL] [Abstract][Full Text] [Related]
20. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.
Hodges AK; Li S; Maynard J; Parry L; Braverman R; Cheadle JP; DeClue JE; Sampson JR
Hum Mol Genet; 2001 Dec; 10(25):2899-905. PubMed ID: 11741833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
